What Analysts Are Saying About Axsome Therapeutics Stock

Ratings for Axsome Therapeutics AXSM were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Axsome Therapeutics and provided 12-month price targets. The average target is $123.46, accompanied by a high estimate of $180.00 and a low estimate of $103.00. This upward trend is evident, with the current average reflecting a 16.47% increase from the previous average price target of $106.00.

Understanding Analyst Ratings: A Comprehensive Breakdown

The perception of Axsome Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axsome Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axsome Therapeutics compared to the broader market.
• Price Targets: Delving into movements, analysts provide estimates for the future value of Axsome Therapeutics's stock. This analysis reveals shifts in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Axsome Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Axsome Therapeutics analyst ratings.

Discovering Axsome Therapeutics: A Closer Look

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Axsome Therapeutics: Delving into Financials

Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.

Revenue Growth: Axsome Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 193.5%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Axsome Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -137.92%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Axsome Therapeutics's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -42.85%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -16.59%, the company may face hurdles in achieving optimal financial returns.

Debt Management: Axsome Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 0.98. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Significance of Analyst Ratings Explained

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.